The head of the Food and Drug Administration said Tuesday that the agency is now looking at whether it will still approve COVID-19 vaccines for next winter, citing a lack of data on booster shots.

In an interview with Dr. Phil, the health secretary offered false information about vaccine oversight and revealed a lack of ...

While Novartis holds a diversified product portfolio, there is some product concentration with its largest drugs, Entresto (close to 15% of sales) and Cosentyx (close to 10% of sales). Both drugs will ...

FDA vaccine oversight is shifting, with increased scrutiny and mixed messaging sparking concerns among health experts.

Novavax’s COVID-19 vaccine could soon receive full approval from the United States Food and Drug Administration.

Among other things, Makary breaks some news here by stating, for the first time, that there will be no significant ...

There is common ground. Most adults favor: Preventing chronic diseases (Republicans 86%, Democrats 91%) Protecting against ...

NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company”), and a leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine ...

The President Donald Trump administration's request for Novavax Inc. to conduct new clinical trials for its COVID-19 vaccine ...

Kennedy won Senate confirmation to his job, in part, by promising not to change the nation’s vaccine schedule. Since taking ...

Novavax said Monday that the FDA was asking the company to run a new clinical trial of its vaccine after the agency grants full approval. The company said it had responded and tha ...